SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-23-000154
Filing Date
2023-08-09
Accepted
2023-08-09 07:03:41
Documents
14
Period of Report
2023-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20230809.htm   iXBRL 8-K 33700
2 EX-99.1 zntl_q2x2023earningsprxcle.htm EX-99.1 61381
6 zenalis_primarybluenavy.jpg GRAPHIC 68307
  Complete submission text file 0001725160-23-000154.txt   323772

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20230809.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20230809_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20230809_pre.xml EX-101.PRE 13048
8 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20230809_htm.xml XML 2821
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 231153317
SIC: 2834 Pharmaceutical Preparations